Head-to-head evidence
Resmetirom vs VK2809
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
MASH / NASH
Shared mechanism: Thyroid hormone receptor-beta · full MASH / NASH pipeline
Resmetirom · Rezdiffra
Marketed by Madrigal Pharmaceuticals
NCT04197479 · Phase 3 · completed
The study randomized 1,343 participants and included quadruple-blinded, placebo-controlled treatment arms, although it also had an open-label resmetirom arm. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: October 2026 · NCT07249788 (registry estimate)
VK2809
Developed by Viking Therapeutics
NCT04173065 · Phase 2 · completed
This randomized, quadruple-blind, placebo-controlled Phase 2b trial (n=248) in biopsy-confirmed NASH measured its primary result using an imaging-based marker of liver fat (MRI-PDFF) rather than the liver biopsy assessment typically used to support NASH drug approvals. VK2809 produced a significant, dose-dependent reduction in liver fat versus placebo at 12 weeks, up to 51.7% (p<0.0001), a promising early signal that still needs confirmation on the histological outcome collected later in the study.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Resmetirom's landscape · VK2809's landscape